CV Sciences’ Q1 Sales Tumble, And COVID-19’s Only Part Of The Problem

Store closures in the natural product channel did no favors for CV Sciences in March, but the 45% decrease in its first-quarter sales reflects pressures that were weighing on its consumer business before the pandemic struck. The PlusCBD product manufacturer remains confident about its long-term prospects in what it expects to be a more sensibly regulated marketplace versus the status quo.